NBC Los Angeles3h
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
BioPharma Dive6h
Bluebird, at risk of default, agrees to take-private deal
The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...
FiercePharma7h
Once valued at $10B, bluebird bio sold to private equity firms for $29M
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
bluebird bio plunges after take-private deal with Carlyle and SK Capital
(NASDAQ:BLUE) lost ~37% in the premarket on Friday after the gene therapy developer announced its plans to become a privately held biotech as part of an M&A agreement with private equity firms Carlyle ...
Analysts Conflicted on These Consumer Cyclical Names: Blue Bird (BLBD) and Alibaba (BABA)
Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on Blue Bird (BLBD – Research Report) and Alibaba (BABA ...